Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Daclizumab para la esclerosis múltiple recurrente remitente

Información

DOI:
https://doi.org/10.1002/14651858.CD008127.pub4Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 23 diciembre 2013see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Esclerosis múltiple y enfermedades raras del sistema nervioso central

Copyright:
  1. Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Jia Liu

    Correspondencia a: Department of Geriatric Neurology, Chinese PLA General Hospital, Beijing, China

    [email protected]

  • Lu‐Ning Wang

    Department of Geriatric Neurology, Chinese PLA General Hospital, Beijing, China

  • Siyan Zhan

    Centre for Evidence Based Medicine and Clinical Research, School of Public Health, Peking University, Beijing, China

  • Yinyin Xia

    Dept. of Surveillance and Statistics, National Center for TB Control and Prevention, China CDC, Beijing, China

Contributions of authors

Liu J and Wang L formulated the idea and developed the basis for the review.

Zhan S and Xia Y supervised the methodology and statistics.

Liu J and Wang L were in charge of updating the review.

Sources of support

Internal sources

  • Department of Geriatric Neurology, Chinese PLA General Hospital, China.

External sources

  • No sources of support supplied

Declarations of interest

None known.

Acknowledgements

The authors would like to acknowledge the help provided by Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group.

Version history

Published

Title

Stage

Authors

Version

2013 Dec 23

Daclizumab for relapsing remitting multiple sclerosis

Review

Jia Liu, Lu‐Ning Wang, Siyan Zhan, Yinyin Xia

https://doi.org/10.1002/14651858.CD008127.pub4

2012 Apr 18

Daclizumab for relapsing remitting multiple sclerosis

Review

Jia Liu, Luning Wang, Si‐Yan Zhan, Yinyin Xia

https://doi.org/10.1002/14651858.CD008127.pub3

2010 Jun 16

Daclizumab for relapsing remitting multiple sclerosis

Review

Jia Liu, Luning Wang, Siyan Zhan, Jiping Tan, Yinyin Xia

https://doi.org/10.1002/14651858.CD008127.pub2

2009 Oct 07

Daclizumab for relapsing remitting multiple sclerosis

Protocol

Jia Liu, Luning Wang, Siyan Zhan, Jiping Tan, Yinyin Xia

https://doi.org/10.1002/14651858.CD008127

Differences between protocol and review

None.

Keywords

MeSH

Medical Subject Headings (MeSH) Keywords

Medical Subject Headings Check Words

Humans;

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.

Study flow diagram.
Figuras y tablas -
Figure 1

Study flow diagram.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figuras y tablas -
Figure 2

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figuras y tablas -
Figure 3

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Safety, Outcome 1 Any adverse event.
Figuras y tablas -
Analysis 1.1

Comparison 1 Safety, Outcome 1 Any adverse event.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Safety, Outcome 2 Serious adverse event.
Figuras y tablas -
Analysis 1.2

Comparison 1 Safety, Outcome 2 Serious adverse event.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Comparison 1. Safety

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Any adverse event Show forest plot

2

851

Risk Ratio (M‐H, Random, 95% CI)

0.98 [0.89, 1.07]

2 Serious adverse event Show forest plot

2

851

Risk Ratio (M‐H, Random, 95% CI)

1.15 [0.29, 4.54]
Figuras y tablas -
Comparison 1. Safety
Ir a la tabla de la revisión